CLOs on the Move


 
Right from the beginning, which is now more than fifty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task` Today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge` Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability` Bruker continues to build upon its extensive range of products and solutions, expand its broad base of ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.bruker.com
  • 40 Manning Road
    Billerica, MA USA 01821
  • Phone: 978.663.3660

Executives

Name Title Contact Details
Kristin Caplice
Senior Vice President, General Counsel and Global Head of Corporate Compliance Profile
Brent Alldredge
General Counsel Profile

Similar Companies

Dova Pharmaceuticals

Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...

Christian Counseling Center

Christian Counseling Center is a Orland Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adrian Elwell at Au Top

Adrian Elwell at Au Top is a Danville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.

Precision NanoSystem

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.